Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Xencor, Inc.
Incyte Corporation
Novartis
Takeda
Novartis
Cellerant Therapeutics
Synta Pharmaceuticals Corp.
INSYS Therapeutics Inc
Millennium Pharmaceuticals, Inc.
Novartis
Daiichi Sankyo
Bristol-Myers Squibb
Bristol-Myers Squibb